SQI in Can$7m private placement:
This article was originally published in Clinica
Executive Summary
Toronto, Ontario-based SQI Diagnostics has announced a private placement offering of up to Can$7m ($6.6m) of units of the company. Each unit will consist of one share and one half of a share purchase warrant. The holder of a whole warrant will be entitled to acquire one share within two years after completion of the offering. Research Capital and Kinsdale Capital Markets have been appointed as agents of the transaction. SQI develops automated diagnostic systems for high-volume, multiple biomarker testing. Targeting the US$1.4bn autoimmune disease market, the company is expecting to launch its first products for rheumatoid arthritis and thrombosis in 2007.
You may also be interested in...
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.